Organization (Industry)
ALK-Abelló (Netherlands)
ClinicalTrials.gov lists ALK-Abelló (Netherlands) as lead sponsor of 67 trials. It has 7 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ALK-Abelló (Netherlands): 67 lead-sponsored trials and 5 legal-entity registrations.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Rhinitis, Allergic | 30 |
| Asthma | 9 |
| Rhinitis, Allergic, Perennial | 7 |
| Rhinitis, Allergic, Seasonal | 7 |
| Dust Mite Allergy | 2 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 2 |
| 2015 | 1 |
| 2014 | 3 |
| 2013 | 5 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 67 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| HDM SLIT-tablet | Rhinitis, Allergic | Phase 3 | 3 |
| Sublingual allergy immunotherapy tablet | Rhinitis, Allergic | Phase 3 | 1 |
| Peanut SLIT-tablet | Food Hypersensitivity | Phase 1/2 | 1 |
| Peanut SLIT-tablet | Peanut Hypersensitivity | Phase 1/2 | 1 |
| Observational | Rhinitis, Allergic | Not reported | 1 |
Showing 5 of 7 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| GRAZAX | 6 |
| Rescue Medication | 1 |
| MK-7243 2800 BAU (Timothy grass extract) | 1 |
| MK-3641 12 Amb a 1-U (short ragweed extract) | 1 |
| Pangramin Plus D. pteronyssinus 100% | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=12) | 17% on time (n=12) |
Journals published in (30)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of allergy and clinical immunology | 15 |
| Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 14 |
| Allergy | 5 |
| Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology | 2 |
| Clinical and translational allergy | 2 |
Showing 5 of 30 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 27 | 2 | 2022-06-28 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2025-03-07 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Alk-abello A/s | Horsholm, DK | EMA, FDA, Health Canada |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Syneos Health (United States) | Uses vendor | 2 |
| Parexel | Uses vendor | 2 |
| Ergomed | Uses vendor | 2 |
Latest dated events (116)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-07 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2023-11-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 116 events.
Biomarker capability evidence (79)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APOH | Trial collaborator | Named in trial inclusion criteria |
| ARC | Trial sponsor | Named in trial inclusion criteria |
| NF2 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| NOL3 | Trial sponsor | Named in trial inclusion criteria |
| PSMB7 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 79 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.